Technical Analysis for RNAC - Cartesian Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 200 DMA Resistance | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | 0.00% | |
| Spinning Top | Other | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Multiple of Ten Bearish | Other | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| BB Squeeze Started | Range Contraction | 0.00% | |
| Inside Day | Range Contraction | 0.00% | |
| Below Lower BB | Weakness | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% |
| Alert | Time |
|---|---|
| Down 3% | about 19 hours ago |
| Down 2 % | about 19 hours ago |
| Possible NR7 | about 19 hours ago |
| Possible Inside Day | about 19 hours ago |
| Down 1% | about 20 hours ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 11/11/2024
Cartesian Therapeutics is a clinical-stage company pioneering RNA cell therapies for the treatment of autoimmune diseases. The company’s lead asset, Descartes-08, is a potential first-in-class, RNA-engineered chimeric antigen receptor T-cell therapy (rCAR-T) in Phase 2b clinical development for patients with generalized myasthenia gravis, with additional Phase 2 studies planned in systemic lupus erythematosus as well as ocular autoimmune and vasculitic autoimmune basket trials. Cartesian operates a wholly owned, state-of-the-art cGMP manufacturing facility in Gaithersburg, MD.
Sector: Healthcare
Industry: Biotechnology
Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Autoimmune Disease Cell Therapy Autoimmunity Lupus Myasthenia Gravis Sjögren Syndrome Systemic Lupus Erythematosus Therapies For The Treatment Of Autoimmune Diseases
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 42.6 |
| 52 Week Low | 11.665 |
| Average Volume | 92,127 |
| 200-Day Moving Average | 20.25 |
| 50-Day Moving Average | 18.24 |
| 20-Day Moving Average | 21.80 |
| 10-Day Moving Average | 21.48 |
| Average True Range | 1.96 |
| RSI (14) | 46.52 |
| ADX | 26.94 |
| +DI | 15.48 |
| -DI | 16.68 |
| Chandelier Exit (Long, 3 ATRs) | 19.63 |
| Chandelier Exit (Short, 3 ATRs) | 23.58 |
| Upper Bollinger Bands | 23.88 |
| Lower Bollinger Band | 19.71 |
| Percent B (%b) | -0.01 |
| BandWidth | 19.13 |
| MACD Line | 0.57 |
| MACD Signal Line | 1.05 |
| MACD Histogram | -0.4872 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 22.14 | ||||
| Resistance 3 (R3) | 22.24 | 21.52 | 21.73 | ||
| Resistance 2 (R2) | 21.52 | 20.89 | 21.47 | 21.59 | |
| Resistance 1 (R1) | 20.60 | 20.51 | 20.24 | 20.50 | 21.46 |
| Pivot Point | 19.88 | 19.88 | 19.70 | 19.83 | 19.88 |
| Support 1 (S1) | 18.96 | 19.25 | 18.60 | 18.86 | 17.90 |
| Support 2 (S2) | 18.24 | 18.87 | 18.19 | 17.77 | |
| Support 3 (S3) | 17.32 | 18.24 | 17.63 | ||
| Support 4 (S4) | 17.22 |
